We are live on
!
Find out more
BCP
Blue Chip Partners Portfolio holdings
AUM
$1.58B
1-Year Est. Return
32%
This Fund
S&P 500
This Quarter
Est. Return
+4.08%
1 Year Est. Return
+32%
3 Year Est. Return
+81.22%
5 Year Est. Return
+95.38%
10 Year Est. Return
+314.48%
AUM
$473M
AUM Growth
+$26.5M
(+5.9%)
Cap. Flow
+$10.4M
Cap. Flow
% of AUM
2.2%
Top 10 Holdings %
Top 10 Hldgs %
33.34%
Holding
143
New
10
Increased
100
Reduced
26
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$981K |
| 2 |
JPMorgan Ultra-Short Income ETF
JPST
|
+$968K |
| 3 |
UnitedHealth
UNH
|
+$711K |
| 4 |
Amgen
AMGN
|
+$617K |
| 5 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
+$512K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$1.67M |
| 2 |
Schwab US Dividend Equity ETF
SCHD
|
+$364K |
| 3 |
Vanguard High Dividend Yield ETF
VYM
|
+$362K |
| 4 |
Vanguard Dividend Appreciation ETF
VIG
|
+$345K |
| 5 |
DuPont de Nemours
DD
|
+$189K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 19.38% |
| 2 | Technology | 11.55% |
| 3 | Healthcare | 11.5% |
| 4 | Consumer Staples | 11.43% |
| 5 | Industrials | 10.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Sysco
SYY
$39.3B
| $158K | 0.03% |
1,993
+439
| +28% | +$32.2K |
|
127
Meta Platforms (Facebook)
META
$1.47T
| $153K | 0.03% |
857
+45
| +6% | +$8.55K |
|
128
Nike
NKE
$58.7B
| $152K | 0.03% |
1,622
+5
| +0.3% | +$429 |
|
129
iShares Core US Aggregate Bond ETF
AGG
$138B
| $146K | 0.03% |
1,293
-145
| -10% | -$16.3K |
|
130
Emerson Electric
EMR
$86.6B
| $139K | 0.03% |
2,076
+16
| +0.8% | +$1.01K |
|
131
Broadcom
AVGO
$1.75T
| $137K | 0.03% |
+4,970
| New | +$141K |
|
132
W.P. Carey
WPC
$16.1B
| $130K | 0.03% |
+1,484
| New | +$126K |
|
133
MGE Energy Inc
MGEE
$2.95B
| $120K | 0.03% |
+1,500
| New | +$112K |
|
134
Colgate-Palmolive
CL
$72.3B
| $114K | 0.02% |
1,550
+10
| +0.6% | +$725 |
|
135
Air Products & Chemicals
APD
$68.6B
| $112K | 0.02% |
507
+66
| +15% | +$14.8K |
|
136
Aflac
AFL
$58.4B
| $109K | 0.02% |
2,080
+7
| +0.3% | +$370 |
|
137
Vanguard FTSE All-World ex-US ETF
VEU
$70.4B
| $108K | 0.02% |
2,161
-28
| -1% | -$1.4K |
|
138
General Mills
GIS
$22.2B
| $106K | 0.02% |
+1,924
| New | +$104K |
|
139
Starbucks
SBUX
$123B
| $102K | 0.02% |
+1,152
| New | +$107K |
|
140
Stanley Black & Decker
SWK
$14.8B
| $102K | 0.02% |
708
+2
| +0.3% | +$283 |
|
|
141
DuPont de Nemours
DD
$18.5B
| – | – |
-2,008
| Closed | -$189K |
|
142
Dow Inc
DOW
$22B
| – | – |
-2,279
| Closed | -$112K |
|
|
143
Schwab US Dividend Equity ETF
SCHD
$111B
| – | – |
-20,598
| Closed | -$364K |
|
Similar funds
RWM
LLL
FWP
PIS
RIM
W
GCP
SW
Blue Chip Partners's Q3 2019 Portfolio in Review
As of Q3 2019, Blue Chip Partners held 143 positions worth $473M, up 5.9% from $446M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Blue Chip Partners's Q3 2019 filing shows 10 new, 100 increased, 26 reduced and 3 closed positions. Its largest new stake was Biogen: 960 shares worth $224K. The largest sale was Pfizer, an estimated $1.67M.
By sector, the portfolio is most concentrated in Miscellaneous at 19% of assets, down from 20% a quarter earlier, followed by Technology and Healthcare.
- Blue Chip Partners's largest Q3 2019 buy was Biogen: 960 shares worth $224K.
- Blue Chip Partners added most to AbbVie in Q3 2019, an estimated $981K increase.
- Blue Chip Partners's biggest Q3 2019 reduction was Pfizer, cutting an estimated $1.67M.
- Blue Chip Partners fully exited Schwab US Dividend Equity ETF in Q3 2019, selling an estimated $364K.
- Blue Chip Partners's ten largest holdings make up 33% of its $473M portfolio in Q3 2019.
- Blue Chip Partners opened 10 new positions and closed 3 in Q3 2019.
- Blue Chip Partners's portfolio value rose 5.9% quarter-over-quarter to $473M.
Based on Blue Chip Partners's 13F filing for Q3 2019, filed 29 Oct 2019.